Efficacy and safety of CAStem cell injection in the treatment of acute exacerbation of interstitial lung disease (AE-ILD)

General Information
Clinical trials phase	Phase 2
Start date (estimated)	2023-09-21
End date (estimated)	2025-12-31
Clinical feature	Label interstitial lung disease Link http://purl.obolibrary.org/obo/DOID_3082 Description A lung disease that is characterized by inflammation and altered lung interstitium compromising pulmonary function and often has_symptom shortness of breath, dyspnea, and/or cough.
Administrative Information
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2400081256
Other study identifiers	Name ChiCTR2400081256 Description Chinese Clinical Trial Registry (ChiCTR)
Source weblink	https://www.chictr.org.cn/showproj.html?proj=201722
Public contact	Email fangyan.chen@zephyrm.com Public email fangyan.chen@zephyrm.com First name Chen Last name Fangyan Phone +86 134 6670 3262 City Beijing Country China Address freetext 27 Middle of North Fourth Ring Road, Chaoyang District, Beijing
Sponsors	China-Japan Friendship Hospital
Cells
Recruitment
Recruitment Status	Recruiting
Estimated number of participants	45